Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-209-FSP-B1
- Development stage
- Unknown
- Lead developer
- Nouscom
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MVA-209-FSP-B1 is a viral vector-based cancer vaccine component developed by Nouscom, utilizing the Modified Vaccinia Ankara (MVA) platform. It is specifically designed as one of the 'boost' vectors in the NOUS-209 heterologous prime-boost vaccine regimen. NOUS-209 targets 209 shared frameshift peptide (FSP) neoantigens that are frequently generated in tumors with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR), such as colorectal, gastric, and endometrial cancers. Because of the large number of antigens encoded, the payload is distributed across multiple vectors (e.g., B1 and B2). The regimen typically begins with a priming dose using Great Ape Adenovirus vectors (GAd209-FSP) followed by boosting with MVA vectors like MVA-209-FSP-B1. The vaccine aims to induce a broad, polyfunctional CD8+ and CD4+ T-cell response against multiple tumor antigens simultaneously to overcome tumor heterogeneity and prevent immune escape.
- Other names
- MVA-209-FSP-B1MVA209-FSP-B1MVA 209-FSP-B1
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on MVA-209-FSP-B1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-209-FSP-B1.